Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer

QR Code

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer

BackgroundWhether the addition of trastuzumab to chemo(immuno)therapy for the preoperative treatment of patients with potentially resectable HER2-positive gastric cancer has clinical benefits remains to be explored. This real-world observational study was designed to evaluate the efficacy and safety...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xuchen Zhang, Yulong Tian, Huiyun Wang, Shanai Song, Yunqing Chen, Ning Liu, Chuantao Zhang, Xiao Huang, Haitao Jiang, Helei Hou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Immunology
Subjects:	HER2-positive gastric cancer preoperative therapy trastuzumab immune checkpoint blockade tumour regression grade
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1624943/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
by: Mark Hensley, et al.
Published: (2025-07-01)

Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer
by: Frankie Ann Holmes, et al.
Published: (2018-06-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report
by: Ayaka Isogai, et al.
Published: (2023-06-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01)

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)
by: H. C. Chung, et al.
Published: (2017-02-01)

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01)

Long-term survival after multidisciplinary treatments for HER2-positive advanced gastric cancer with multiple liver and lung metastases
by: Satoshi Yoshioka, et al.
Published: (2023-08-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Detection of anti-drug antibodies to trastuzumab in serum by enzyme-linked immunosorbent assay
by: V. V. Pisarev, et al.
Published: (2025-06-01)

HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01)

Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti‐HER2 Therapy) and Radiotherapy: Systematic Review and Meta‐Analysis
by: Ali Jabbari, et al.
Published: (2025-06-01)

Development and Validation of the ELISA Method for Anti-trastuzumab Antibodies Determination in Human Serum
by: O. A. Eliseeva, et al.
Published: (2022-12-01)

Validation of ELISA Test-system for Trastuzumab (Herceptin, Hertikad) quantitative determination in biological fluids
by: V. V. Pisarev, et al.
Published: (2023-05-01)

Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer
by: Gavin P. Dowling, et al.
Published: (2025-05-01)

Clinical case of a successful treatment of stage IV esophagal adenocarcinoma
by: A. V. Sergeeva, et al.
Published: (2022-05-01)

Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
by: Hiromi Nagata, et al.
Published: (2020-01-01)

The influence of H. pylori infection in HER2-positive gastric cancer cell lines: insights from Wnt/β-catenin pathway
by: Valli De Re, et al.
Published: (2025-06-01)

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review
by: I. V. Kolyadina
Published: (2023-10-01)

Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia
by: N. A. Avxentyev, et al.
Published: (2024-07-01)

Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis
by: Xuan Ye, et al.
Published: (2025-08-01)

Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer
by: Heves Surmeli, et al.
Published: (2025-06-01)

Development and Validation of the ELISA Method for Neutralizing Anti-trastuzumab Antibodies Detection in Human Blood Serum
by: M. A. Kolganova, et al.
Published: (2023-05-01)

A Double-blind Randomized Comparative Phase I Study to Assess Biosimilarity and Immunogenicity of "Trastuzumab" (LLC "Mabscale", Russia) and Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Volunteers
by: M. A. Kolganova, et al.
Published: (2023-09-01)

Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy
by: Koichi Hayano, et al.
Published: (2020-09-01)

A Mathematical Model for Complete Morphological Regression in Primary Operable HER2-Positive Breast Cancer
by: A. E. Orlov, et al.
Published: (2021-04-01)

Immunosuppressive mechanisms and therapeutic targeting of regulatory T cells in ovarian cancer
by: Jing Li, et al.
Published: (2025-07-01)

RADIATION-INDUCED TOXICITY IN BREAST CANCER PATIENTS TREATED WITH TRASTUZUMAB-BASED CHEMOTHERAPY
by: R. Yu. Karabut, et al.
Published: (2021-08-01)

Immunohistochemical Profiling of Immune Checkpoints in Chronic Hepatitis B Liver Tissue
by: João Panão-Costa, et al.
Published: (2025-06-01)

Successful subtotal gastrectomy and hepatectomy for HER2-positive gastric cancer with liver metastasis after trastuzumab-based chemotherapy: a case report
by: Yuki Hirase, et al.
Published: (2024-03-01)

In Vitro Evaluation of the Efficient Passage of PLGA-Formulated Trastuzumab for Nose-to-Brain Delivery
by: Léa Kengne Kamkui, et al.
Published: (2025-05-01)

PREOPERATIVE PLANNING USING MEDICAD SOFTWARE (GERMANY)
by: Petar Angelov, et al.
Published: (2023-09-01)

De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trialResearch in context
by: Hong Pan, et al.
Published: (2025-08-01)

Preoperative preparation of patients for aortic aneurysm surgery
by: Yu. V. Belov, et al.
Published: (2014-03-01)

Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
by: Yan Zhang, et al.
Published: (2019-08-01)

Impact of Premedication on Preoperative Anxiety in Females with Gynecological Diseases
by: I. G. Bobrinskaya, et al.
Published: (2007-08-01)

The importance of preoperative preparation of pediatric patients
by: Dušica Simić, et al.
Published: (2025-06-01)